The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users

Addiction

Volumn 109, Issue 12, 2014, Pages 2053-2059

  Nolan, Seonaid ^a,b   Dias Lima, Viviane ^a,b   Fairbairn, Nadia ^a   Kerr, Thomas ^a,b   Montaner, Julio ^a,b   Grebely, Jason ^a,c   Wood, Evan ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HCV; Hepatitis C; Illicit drug use; Incident infection; Methadone; Opioid; Seroconversion

Indexed keywords

METHADONE; STREET DRUG;

ADULT; ALCOHOLISM; BRITISH COLUMBIA; COHORT ANALYSIS; FEMALE; HEPATITIS C; HUMAN; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDY; SEROCONVERSION; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

ADULT; ALCOHOLISM; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROSPECTIVE STUDIES; SEROCONVERSION; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84920490123     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12682     Document Type: Article

References (47)

1. Haydon E., Fischer B., Krajden M. Hepatitis C virus (HCV) infection and illicit drug use [Internet]. Ottawa: Canadian Centre of Substance Abuse. 2005 (cited 18 January 2014). Available at: http://www.ccsa.ca/Resource%20Library/ccsa-004030-2005.pdf (accessed 19 June 2014) (archived at http://www.webcitation.org/6QS7hPs7j on 19 June 2014).
2. Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
3. Fischer B. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach-the case study of Canada. J Urban Health 2004; 81: 428-447.
4. Alavian S.-M., Mirahmadizadeh A., Javanbakht M., Keshtkaran A., Heidari A., Mashayekhi A. etal. Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users. Hepat Mon 2013; 13: 1-6.
5. Seeff L. B. Natural history of hepatitis C. Hepatology 1997; 26: 21S-28.
6. Perz J. F., Armstrong G. L., Farrington L. A., Hutin Y. J. F., Bell B. P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
7. Dinner K., Donaldson T., Potts J., Sirna J., Wong T. Hepatitis C: a public health perspective and related implications for physicians. Public Health Agency of Canada. R Coll Outlook 2005; 2: 20-22.
8. Alter M. J., Kruszon-Moran D., Nainan O. V., McQuillan G. M., Gao F., Moyer L. A. etal. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
9. Hajarizadeh B., Grebely J., Dore G. J. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562.
10. Nelson P. K., Mathers B. M., Cowie B., Hagan H., Jarlais, Des D., Horyniak D. etal. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
11. Hagan H., Pouget E. R., Williams I. T., Garfein R. L., Strathdee S. A., Hudson S. M. etal. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis 2010; 201: 378-385.
12. Roy E., Alary M., Morissette C., Leclerc P., Boudreau J.-F., Parent R. etal. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007; 18: 23-27.
13. Maher L., Jalaludin B., Chant K. G., Jayasuriya R., Sladden T., Kaldor J. M. etal. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006; 101: 1499-1508.
14. Page K., Hahn J. A., Evans J., Shiboski S., Lum P., Delwart E. etal. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-1226.
15. Bruneau J., Roy E., Arruda N., Zang G., Jutras-Aswad D. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012; 107: 1318-1327.
16. Roy E., Boudreau J.-F., Boivin J.-F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 2009; 102: 158-161.
17. Hagan H., Pouget E. R., Des Jarlais D. C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83.
18. Somaini B., Wang J., Perozo M., Kuhn F., Meili D., Grob P. etal. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care 2000; 12: 449-460.
19. Taylor A., Goldberg D., Hutchinson S., Cameron S., Gore S. M., McMenamin J. etal. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working? J Infect 2000; 40: 176-183.
20. Craine N., Hickman M., Parry J. V., Smith J., Walker A. M., Russell D. etal. Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect 2009; 137: 1255-1265.
21. Vickerman P., Martin N., Turner K., Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 2012; 107: 1984-1995.
22. McGowan C., Harris M., Rhodes T. Hepatitis C avoidance in injection drug users: a typology of possible protective practices. PLOS ONE 2013; 8: e77038.
23. Fairbairn N., Hayashi K., Kaplan K., Suwannawong P., Qi J., Wood E. etal. Factors associated with methadone treatment among injection drug users in Bangkok, Thailand. J Subst Abuse Treat 2012; 43: 108-113.
24. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301.
25. Mathers B. M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R. P. etal. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-1028.
26. Nosyk B., Sun H., Evans E., Marsh D. C., Anglin M. D., Hser Y.-I. etal. Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction 2012; 107: 1621-1629.
27. Kerr T., Marsh D., Li K., Montaner J., Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend 2005; 80: 329-335.
28. Strathdee S. A., Palepu A., Cornelisse P. G., Yip B., O'Shaughnessy M. V., Montaner J. S. etal. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998; 280: 547-549.
29. Wood E., Hogg R. S., Lima V. D., Kerr T., Yip B., Marshall B. D. L. etal. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300: 550-554.
30. Wood E., Hogg R. S., Bonner S., Kerr T., Li K., Palepu A. etal. Staging for antiretroviral therapy among HIV-infected drug users. JAMA 2004; 292: 1175-1177.
31. Wood E., Stoltz J.-A., Montaner J. S. G., Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J 2006; 3: 18.
32. Kerr T., Small W., Johnston C., Li K., Montaner J. S. G., Wood E. Characteristics of injection drug users who participate in drug dealing: implications for drug policy. J Psychoact Drugs 2008; 40: 147-152.
33. DeBeck K., Kerr T., Li K., Fischer B., Buxton J., Montaner J. etal. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Can Med Assoc J 2009; 181: 585-589.
34. Diggle P. J., Heagerty P., Liang K. Y., Zegger S. L. Analysis of Longitudinal Data, 2nd edn. Oxford, UK: Oxford University Press; 2002.
35. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.
36. Miller C. L., Johnston C., Spittal P. M., Li K., Laliberte N., Montaner J. etal. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737-742.
37. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse 1998; 33: 1197-1212.
38. Noori R., Narenjiha H., Aghabakhshi H., Habibi G., Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse 2012; 47: 767-773.
39. Dolan K. A., Shearer J., White B., Zhou J., Kaldor J., Wodak A. D. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction 2005; 100: 820-828.
40. Crofts N., Nigro L., Oman K., Stevenson E., Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction 1997; 92: 999-1005.
41. Turner K. M. E., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. etal. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-1988.
42. Mattick R. P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
43. Gowing L. R., Farrell M., Bornemann R., Sullivan L. E., Ali R. L. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21: 193-195.
44. Schechter M. T., Strathdee S. A., Cornelisse P. G., Currie S., Patrick D. M., Rekart M. L. etal. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. AIDS 1999; 13: F45-51.
45. Des Jarlais D., Paone D., Milliken J., Turner C., Miller C., Gribble J. etal. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 1999; 353: 1657-1661.
46. Jurgens R., Csete J., Amon J. J., Baral S., Beyrer C. People who use drugs, HIV, and human rights. Lancet 2010; 376: 475-485.
47. Nosyk B., Anglin M. D., Brissette S., Kerr T., Marsh D. C., Schackman B. R. etal. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood) 2013; 32: 1462-1469.